{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:32:13Z","timestamp":1790253133205,"version":"4.1.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T00:00:00Z","timestamp":1497225600000},"content-version":"vor","delay-in-days":162,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Drug-induced liver injury related to Triumeq (abacavir\/lamivudine\/dolutegravir) has not been reported in clinical trials. We report a case of hepatotoxicity related to Triumeq exposure in a human immunodeficiency virus\u2013infected patient. Clinicians should remain aware of the risk for acute and late-onset hepatitis with these agents. Close monitoring is recommended.<\/jats:p>","DOI":"10.1093\/ofid\/ofx122","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T13:09:02Z","timestamp":1497272942000},"source":"Crossref","is-referenced-by-count":15,"title":["Abacavir\/Dolutegravir\/Lamivudine (Triumeq)\u2013Induced Liver Toxicity in a Human Immunodeficiency Virus\u2013Infected Patient"],"prefix":"10.1093","volume":"4","author":[{"given":"Erin S.","family":"Christensen","sequence":"first","affiliation":[{"name":"Department of Pharmacy Services, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Roxby","sequence":"additional","affiliation":[{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,12]]},"reference":[{"key":"2020081005183583600_CIT0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"key":"2020081005183583600_CIT0002","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.clinre.2013.02.008","article-title":"Hepatoxicity of new antiretrovirals: a systematic review","volume":"37","author":"Surgers","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2020081005183583600_CIT0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2020081005183583600_CIT0004","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/hep.23716","article-title":"Clinical syndromes and consequences of antiretroviral-related hepatotoxicity","volume":"52","author":"N\u00fa\u00f1ez","year":"2010","journal-title":"Hepatology"},{"key":"2020081005183583600_CIT0005"},{"key":"2020081005183583600_CIT0006","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bjid.2016.03.002","article-title":"Abacavir-induced liver toxicity","volume":"20","author":"Pezzani","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"2020081005183583600_CIT0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/QAD.0000000000000139","article-title":"Abacavir-induced liver toxicity in an HIV-infected patient","volume":"28","author":"Di Filippo","year":"2014","journal-title":"AIDS"},{"key":"2020081005183583600_CIT0008","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1097\/QAD.0b013e32831c8af4","article-title":"Abacavir-induced hepatoxicity: a report of 2 cases","volume":"22","author":"Soni","year":"2008","journal-title":"AIDS"},{"key":"2020081005183583600_CIT0009","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"2020081005183583600_CIT0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1310\/hct1505-199","article-title":"Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients","volume":"15","author":"Curtis","year":"2014","journal-title":"HIV Clin Trials"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/3\/ofx122\/33622652\/ofx122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/3\/ofx122\/33622652\/ofx122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T09:25:02Z","timestamp":1597051502000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofx122\/3866833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofx122","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017]]},"published":{"date-parts":[[2017]]},"article-number":"ofx122"}}